Addex Therapeutics Ltd. Q3 2025 shareholders' equity drops 54% to CHF 6.0 million

Addex Therapeutics Ltd. reported its financial results for the third quarter (Q3) and nine-month (9M) period ended September 30, 2025. Income for the nine-month period declined by 62 percent to CHF 0.2 million, primarily due to the completion of the R&D collaboration phase of its agreement with Indivior. For Q3 2025, income totaled CHF 0.05 million. Research and development expenses for the nine-month period were CHF 0.6 million, decreasing by 22 percent. General and administrative expenses amounted to CHF 1.6 million for the same period, representing an 18 percent decrease. Total operating loss for the nine-month period was CHF 2.0 million, narrowing by 12 percent. For Q3 2025, the operating loss was CHF 0.7 million. Net loss per share for the nine-month period was CHF 0.05, compared to a basic and diluted profit per share of CHF 0.08 in the same period of 2024. For Q3 2025, basic and diluted net loss per share stood at CHF 0.01. Cash and cash equivalents as of September 30, 2025, were CHF 2.2 million, down by 35 percent. Shareholders’ equity at the end of the period was CHF 6.0 million, representing a decrease of 54 percent. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001142826-en) on December 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)